Industry

STAAR Surgical Reports Record First Quarter 2026 Financial Results

Vision Monday3d ago1 min read

LAKE FOREST, Calif.—STAAR Surgical Company (NASDAQ: STAA), a global leader in phakic IOLs with the EVO family of Implantable Collamer Lenses (EVO ICL) for vision correction, announced on Wednesday financial results for the first quarter ended April 3, 2026. Net sales for the quarter were $93.5 million, up 119.6 percent from $42.6 million in the prior-year period. This was the highest first quarter net sales in the company's history, STAAR Surgical said. The year-over-year increase in net sales primarily reflected strong performance in China, the company stated, along with double-digit growth in the Americas.

Read full article on Vision Monday

AI Summary

Quick Take

STAAR Surgical reported record-breaking first-quarter net sales of $93.5 million, a staggering 119.6% increase over the $42.6 million earned in the same period last year. This historic performance was driven by an exceptional surge in the Chinese market alongside sustained double-digit growth across the Americas for the EVO ICL product line.

Why It Matters

The massive jump in revenue suggests that phakic IOLs are no longer just a niche alternative to laser vision correction but are becoming a primary driver in the global refractive market. The triple-digit growth indicates that the EVO ICL is successfully capturing a larger share of the myopia correction market, particularly in Asia, while gaining significant traction in the U.S. and surrounding regions. For the industry, this signals a robust recovery or expansion in elective refractive procedures and a potential shift in patient preference toward lens-based, reversible solutions.

Key Details

Net sales reached $93.5 million for the quarter ended April 3, 2026, marking the highest first-quarter revenue in STAAR Surgical's history.
The 119.6% year-over-year growth reflects a significant scaling of the EVO family of Implantable Collamer Lenses (EVO ICL).
Performance in China was cited as a primary driver for the record results, reinforcing the region's status as a critical market for myopia management.
The Americas region maintained strong momentum with double-digit growth, suggesting successful market penetration and surgeon adoption in the U.S.
The financial results highlight a period of rapid acceleration compared to the prior year's $42.6 million in net sales.

Practice Implications

Clinicians should prepare for increased patient awareness and demand for EVO ICL as a primary refractive option rather than just a backup for thin corneas.Practice owners may want to review their refractive surgery marketing and counseling protocols to better integrate lens-based options into their standard offerings.The growth in the Americas suggests that more local peers are adopting this technology, making it a competitive necessity for comprehensive refractive practices.

Who's Affected

Refractive SurgeonsPractice OwnersOptometristsIndustry Analysts

AI-generated summary — always read the original source for full context

Discussion

No comments yet. Be the first to share your thoughts.